MedTrace Logo

Varenicline Light Smoking Pilot

NCT04089982 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2021-05-11

Study results available
· View outcomes & findings →

Summary

The goal of this study is to assess varenicline vs. placebo for its effect on decreasing cue reactivity in light and intermittent smokers.

Conditions

  • Smoking Cessation
  • Smoking Behaviors
  • Smoking

Interventions

DRUG

Varenicline

Chantix

DRUG

Placebo oral tablet

Placebo

Sponsors & Collaborators

Principal Investigators

  • James Davis, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-04
Primary Completion
2020-03-01
Completion
2020-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04089982 on ClinicalTrials.gov